M
Melissa Alsina
Researcher at University of Texas Health Science Center at San Antonio
Publications - 194
Citations - 7526
Melissa Alsina is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 41, co-authored 149 publications receiving 6900 citations. Previous affiliations of Melissa Alsina include University of Texas at San Antonio & Pfizer.
Papers
More filters
Journal ArticleDOI
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
Sundar Jagannath,Bart Barlogie,James R. Berenson,David S. Siegel,D. Irwin,Paul G. Richardson,Ruben Niesvizky,Raymond Alexanian,Steven Limentani,Melissa Alsina,Julian Adams,Michael Kauffman,Dixie Lee Esseltine,David P. Schenkein,Kenneth C. Anderson +14 more
TL;DR: Bortezomib alone or in combination with dexamethasone demonstrated therapeutic activity in patients with multiple myeloma who relapsed after frontline therapy.
Journal ArticleDOI
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson,Emily A. Blood,Constantine S. Mitsiades,Sundar Jagannath,Steven R. Zeldenrust,Melissa Alsina,Robert L. Schlossman,S. Vincent Rajkumar,K. Raman Desikan,Teru Hideshima,Nikhil C. Munshi,Kathleen Kelly-Colson,Deborah Doss,Mary McKenney,Svetlana Gorelik,Diane Warren,Andrea Freeman,Rebecca Rich,Anfang Wu,Marta Olesnyckyj,Kenton Wride,William S. Dalton,Jerome B. Zeldis,Robert Knight,Edie Weller,Kenneth C. Anderson +25 more
TL;DR: Lenalidomide is active and well tolerated in relapsed, refractory myeloma, with the 30-mg once-daily regimen providing the basis for future studies as monotherapy and with dexamethasone.
Journal ArticleDOI
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,David Irwin,Edward A. Stadtmauer,Thierry Facon,Jean-Luc Harousseau,Dina Ben-Yehuda,Sagar Lonial,Hartmut Goldschmidt,Donna E. Reece,Jesús F. San Miguel,Joan Bladé,Mario Boccadoro,Jamie Cavenagh,Melissa Alsina,Vincent Rajkumar,Martha Q. Lacy,Andrzej Jakubowiak,William S. Dalton,Anthony Boral,Dixie-Lee Esseltine,David P. Schenkein,Kenneth C. Anderson +23 more
TL;DR: The activity of bortezomib is confirmed and support extended treatment in relapsed multiple myeloma patients tolerating therapy and among responding patients, 56% improved response with longer therapy beyond initial response, leading to continued improvement in overall quality of response.
Journal ArticleDOI
Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma
Sun Jin Choi,Jose C. Cruz,Fiona E. Craig,Hoyeon Chung,Rowena D. Devlin,G. David Roodman,Melissa Alsina +6 more
TL;DR: High levels of MIP-1 alpha are expressed in marrow samples from patients with MM, but not in marrow from patientsWith other hematologic disorders or controls, and support an important role for MIP -1 alpha as one of the major factors responsible for the increased OCL stimulatory activity in patients with active MM.
Journal ArticleDOI
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
Paul G. Richardson,Robert L. Schlossman,Melissa Alsina,Donna M. Weber,Steven Coutre,Cristina Gasparetto,Sutapa Mukhopadhyay,Michael S. Ondovik,Mahmudul Khan,Carole Paley,Sagar Lonial +10 more
TL;DR: Panobinostat, when combined with bortezomib and dexamethasone, can recapture responses in heavily pretreated, bortzomib-refractory multiple myeloma patients.